- Home
- ALXO vs NAKA Comparison
ALXO vs NAKA Comparison
Compare ALXO & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALXO | NAKA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 196.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | NAKA |
|---|---|---|
| Price | $2.04 | $4.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $3.50 | $0.75 |
| AVG Volume (30 Days) | ★ 1.6M | 270.5K |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,514.38 |
| Revenue Next Year | N/A | $48.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.15 |
| 52 Week High | $2.66 | $16.47 |
Technical Indicators
Market Signals| Indicator | ALXO | NAKA |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 61.68 |
| Support Level | $1.96 | $0.31 |
| Resistance Level | $2.31 | $4.96 |
| Average True Range (ATR) | 0.17 | 0.43 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 28.43 | 81.25 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.